July 26, 2012 — Cambridge Heart Inc., a developer of non-invasive diagnostic tests for cardiac disease, announced that results of a prospective, 155-patient trial reinforces the value of the Microvolt T-Wave Alternans (MTWA) test as a predictor of life-threatening heart rhythms and sudden cardiac death (SCD). The results were published this week in the journal Kardiologia Polska.

July 26, 2012 — Angion Biomedica Corp. announced that the first patient was dosed in a Phase II multicenter clinical trial evaluating BB3 for the treatment of heart attack (acute myocardial infarction). The first patient, a 69-year-old man, was treated at Yale-New Haven Hospital in Connecticut. This double-blind, placebo-controlled study is designed to enroll 80 patients following a first heart attack.

July 25, 2012 — Grady Memorial Hospital has standardized and improved patient education and reduced by 75 percent the amount of time staff spend educating new patients about warfarin by implementing Emmi Solutions’ interactive multimedia program in its Coumadin clinic.

July 24, 2012 — Use of the retrograde approach to revascularizing coronary chronic total occlusions (CTOs) to deliver catheters to the back end of the plug, rather than attacking it head-on, can be far more successful. This was according to research presented during the recent Society of Cardiovascular Angiographic Interventions (SCAI) 2012 Scientific Sessions.

July 23, 2012 — The IT and medical technology company Sectra has acquired the product rights for Intulo, a system that monitors radiation doses, from the Swedish medical IT company Krucom AB. The system enables major time and quality gains in medical care and reduces the risk of patients being exposed to unnecessarily high radiation doses in conjunction with radiology examinations.